Aurinia Pharmaceuticals Inc.
corporate_fare Company Profile
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for AUPH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for AUPH spans 10-Q, 8-K, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- Aurinia 10-Q Details Q3: $83.7M Revenue, $31.7M Net Income, $486.9M Cash
- Aurinia Lifts 2026 Revenue Guidance After Q3 Sales Rise 14%
- Aurinia Settles Teva Patent Litigation, Secures LUPKYNIS Exclusivity Until December 2036
- Aurinia Settles Patent Fight With Teva Over Generic Voclosporin
- Aurinia Q2 2026: LUPKYNIS Sales Surge 19% to $79.4M, Net Income Hits $37.4M
Financial Snapshot
Short Interest & Short Volume
10.31 days to coverFINRA reported short interest of 7,137,632 shares in AUPH as of the October 30, 2026 settlement, a 8.3% decrease from the prior period — about 10.3 days to cover at its recent average daily volume. On November 20, 2026, 31.4% of AUPH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.